Baxter International
About: Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.
Employees: 60,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
19% more call options, than puts
Call options by funds: $132M | Put options by funds: $111M
14% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 8 (+1) [Q3]
13% more capital invested
Capital invested by funds: $15.5B [Q2] → $17.5B (+$2.05B) [Q3]
0.22% less ownership
Funds ownership: 90.78% [Q2] → 90.56% (-0.22%) [Q3]
1% less funds holding
Funds holding: 862 [Q2] → 855 (-7) [Q3]
3% less repeat investments, than reductions
Existing positions increased: 294 | Existing positions reduced: 303
6% less first-time investments, than exits
New positions opened: 113 | Existing positions closed: 120
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Stifel Rick Wise 74% 1-year accuracy 20 / 27 met price target | 19%upside $38 | Buy Maintained | 11 Nov 2024 |
Citigroup Joanne Wuensch 69% 1-year accuracy 27 / 39 met price target | 25%upside $40 | Neutral Maintained | 1 Oct 2024 |
Financial journalist opinion
Based on 16 articles about BAX published over the past 30 days
